Abstract Search - EBCC10

Session title: Keynote Lecture, Oral and Late Breaking Abstracts

Session type: Plenary Session

Track:

Abstract number: 8LBA

Abstract title: LATE BREAKING ABSTRACT: Prospective WSG Phase III PlanB trial: Clinical outcome at 5 year follow-up and impact of 21 Gene Recurrence Score result, central/local-pathological review of grade, ER, PR and Ki67 in HR+/HER2- high risk node-negative and -positive breast cancer

O. Gluz(1), U. Nitz(1), M. Christgen(2), R. Kates(3), M. Clemens(4), S. Krammer(5), B. Nuding(6), B. Aktas(7), S. Lümmel(8), T. Reimer(9), F. Lorenz-Salehi(10), P. Krabisch(11), M. Just(12), D. Augustin(13), C. Liedtke(14), C. Svedman(15), S. Shiek(16), R. Würstlein(17), H. Kreipe(2), N. Harbeck(18)

(1) West German Study Group, Clinical Research, Mönchengladbach, Germany
(2) MHH Hannover, Pathology, Hannover, Germany
(3) West German Study Group, Statistics, Mönchengladbach, Germany
(4) Mutterhaus Trier, Oncology, Trier, Germany
(5) University Clinics Cologne, Gynecology and Obstetrics, Cologne, Germany
(6) LVK Bergisch Gladbach, Gynecology and Obstetrics, Bergisch Gladbach, Germany
(7) University Clinics Essen, Gynecology and Obstetrics, Essen, Germany
(8) Klinikum Essen Mitte, Breast Centre, Essen, Germany
(9) Klinikum Siedstadt, Gynecology and Obstetrics, Rostock, Germany
(10) HSK Wiesbaden, Gynecology and Obstetrics, Wiesbaden, Germany
(11) Klinikum Chemnitz, Gynecology and Obstetrics, Chemnitz, Germany
(12) Oncology Practice, --, Bielefeld, Germany
(13) Klinikum Deggendorf, Breast Centre, Deggendorf, Germany
(14) University Clinics Lübeck, Gynecology and Obstetrics, Lübeck, Germany
(15) Genomic Health Inc., --, Redwood, USA
(16) Genomic Health Inc., --, Redwood, USA
(17) LMU Munich, Gynecology and Obstetrics - Breast Centre, Munich, Germany
(18) LMU Munich, Gynecology and Obstetrics, Munich, Germany

Background: The 21-gene Recurrence Score (RS) assay, nodal status, grade, and immunohistochemical markers are recommended for chemotherapy decision making in HR+/HER2- early breast cancer (EBC). The phase III PlanB trial, prospectively used RS to define a low-risk subset of patients with node negative disease with high risk traditional parameters and patients with node positive disease (HR+, HER2-) who could be treated with adjuvant endocrine therapy alone. We have previously reported the prospectively planned interim analysis at 3-years of clinical outcome and substantial discordance between central and local grade, Ki67 and RS. Here, we report for the first time 5-year outcome data from the trial.

Material and Methods: A central tumor bank was prospectively established within PlanB. Following an early amendment, HR+, pN0-1 patients with RS ≤11 were recommended to omit adjuvant chemotherapy (CT). Patients with RS of 12 or above were randomized to 6× TC vs. 4× EC. 4× Docetaxel chemotherapy. Primary endpoint of the study was disease free survival (DFS), defined as relapse (invasive and non-invasive), secondary malignancy death. Reported survival percentages were based on the Kaplan-Meier estimator. Univariate and multivariate Cox proportional hazard models for DF were performed.

Results: From 2009 to 2011, PlanB enrolled 3198 patients; median age of 56 years; 41.1% had node-positive and 32.5% grade 3 disease. In 348 patients (15.3%), CT was omitted based on RS ≤11. After 55 months median follow-up, 5-year DFS in patients with RS ≤11 and endocrine therapy alone was estimated as 94% vs. 94% (RS 12-25) and 84% (RS >25) in CT-treated patients (p<0.001). Nodal status, central and local grade, Ki-67, ER, PR, tumor size, and RS were univariate prognostic factors for DFS; only pN2–3, both central and local grade, tumor size >2 cm, and fractionally ranked R were independent multivariate factors.

Conclusions: WSG PlanB for the first time shows excellent 5-year DFS of 94% in a population of high risk node-negative and node-positive (pN1) early BC patients (HR+ HER2-) who omitted adjuvant CT based on RS ≤11. Together RS and classical clinical-pathological markers, despite of
substantial heterogeneity in their assessment, provided independent prognostic information. These 5 year outcome data from a prospective trial incorporating the RS support the incorporation of the assay in combination with nodal status, grade and tumor size for adjuvant treatment decisions in early HR+ HER2– BC.

**Conflict of interest:** Advisory Board: Genomic Health.